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Objectives: A common problem in systematic reviews are incomplete data extrac-
tion forms resulting in problems attempting evidence synthesis; we rarely have all 
the data for the endpoints of interest for all studies, and parameters that inform 
meta-analysis or connect networks are missing. Increased transparency in clini-
cal trial reporting means this problem is slowly disappearing. From January 2015 
the European Medicines Agency (EMA) will publish clinical study reports submit-
ted with marketing-authorisation applications for human medicines. MethOds: 
We identified several data sources outside the primary publication. Standard data 
sources for systematic reviews of interventions include peer-reviewed publications, 
conference abstracts and clinical trial registries. Clinical study protocols are often 
published but are not identifiable through searches in online databases, therefore, 
to find these, systematic reviewers must visit the journal website. Manufacturer 
submissions to health regulators are also increasingly made available; these give 
detailed trial descriptions and results presented are more likely to be comprehen-
sive. Results: In a recent example in Hepatitis-C we utilised several additional 
data sources in our evidence synthesis. Clinical trial protocols were used to iden-
tify definitions of endpoints included and to fulfil aspects of the critical appraisal. 
Fibrosis stage is an accepted treatment effect modifier in Hepatitis-C; our review 
therefore collected subgroup data for this. However, this was not readily available 
in peer-reviewed publications; we thus obtained data from EMA submission docu-
ments and UK and German reimbursement submissions. Other examples include a 
2013 COPD systematic review which retrieved mortality data from the FDA website 
for three studies reporting cardiovascular-related death and for one study reporting 
overall death. cOnclusiOns: Systematic reviewers should be aware of additional 
data sources that are publically available. Whilst peer-reviewed data is preferential, 
incorporation of this grey literature into an evidence synthesis could lead to a more 
informed overview of clinical efficacy and thereby healthcare decision making.
PRM15
invEStigation oF RELationShiPS bEtwEEn bioMaRkERS oF PotEntiaL 
haRM anD cigaREttE SMoking MEaSuRES aMong cuRREnt, PaSt, anD 
non-SMokERS baSED on nationaL hEaLth anD nutRition ExaMination 
SuRvEy 2007-2012
Saxena K.1, Liang Q.2, Muhammad-Kah R.2, Sarkar M.2
1Virginia Commonwealth University, Richmond, VA, USA, 2Altria Client Services Inc, Richmond, 
VA, USA
Objectives: Assess the potential relationships between Biomarkers of Potential 
Harm (BOPH), specifically WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol, and biomarkers of cigarette smoke exposure (BOE), specifically serum 
cotinine, creatinine adjusted urinary total NNAL and 1-hydroxypyrene (1-OHP), 
using National Health and Nutrition Examination Survey (NHANES) data from 2007 
till 2012. Secondary objective was to assess the relationship between BOPH and 
smoking status (past, current or never), and cigarette per day (CPD) use in current 
smokers. MethOds: Data were obtained from NHANES 2007 to 2012. The study 
sample included 17,293 respondents age 21 years and above who had answered 
questions on cigarette smoking and had complete laboratory values for their bio-
markers measurement. The population was categorized as current (CS), past (PS), 
and never smokers (NS), based on self-reported responses. The exposure variables 
were the BOE, smoking status and CPD. The outcome variables were levels of the 
BOPH listed above. Weighted survey linear regression was used to estimate the 
association between exposure and outcome variables. The models were adjusted for 
age, gender, race and body mass index (BMI). Results: The mean concentrations of 
WBC (1000 cells/uL) in CS, PS and NS were 8.15, 6.97 and 6.82 respectively, and that 
of HDL (mg/dL) were 49.92, 53.23 and 53.53, respectively. A statistically significant 
correlation was observed for WBC and HDL with serum cotinine (R2= 0.133 and 
0.222), Total NNAL (R2= 0.072 and 0.210) and 1-OHP (R2= 0.090 and 0.186). Similarly, 
significant correlations for WBC and C-reactive protein with smoking status 
(R2= 0.060 and 0.101), and for WBC and HDL with CPD (R2= 0.098 and 0.160) were 
observed. cOnclusiOns: Among all the BOPH, the correlation between WBC and 
HDL were significant with all the cigarette smoking measures. This analysis sug-
gests that WBC and HDL would be useful BOPH in studies addressing health risks 
of cigarette smoking.
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Objectives: Comparative safety assessment can be challenging due to differences 
in safety profiles between comparators, scarcity of data, difficulty in establishing 
causality, and deficiencies in reporting. To address this, a method combining prag-
matic MCDA and advanced statistics was developed and tested by a panel of meth-
odologists and clinical and policy decisionmakers using a case study. MethOds: 
The pragmatic MCDA model categorized adverse events (AEs) generically by their 
clinical consequences into three criteria: ‘non-serious AEs’ (AEs), ‘Non-fatal serious 
AEs’ (SAEs) and ‘Fatal AEs’ (FAEs). Panelists weighted criteria using point allocation. 
Efalizumab for plaque psoriasis, withdrawn in 2009 due to reports of deaths associ-
ated with progressive multifocal leukoencephalopathy (PML), was selected as case 
study. Odds ratios (ORs) for SAEs and AEs were estimated using Bayesian network 
meta-analysis. Incidence of PML was estimated using Poisson modelling. Panelists 
assessed efalizumab safety using a constructed scoring scale for each criterion. 
The approach was re-tested by panelists. Results: Weights for AEs, SAEs and FAEs 
ranged widely between panellist with means (ranges) of 0.06 (0.01-0.1), 0.22 (0.09-
various methods for adjusting confounders in estimating comparative effective-
ness. MethOds: Systematic literature review in PubMed was conducted to iden-
tify published articles with the key words such as propensity score, instrumental 
variable analysis, inverse probability, Propensity Instrumental, Propensity Inverse 
probability, machine learning, support vector machine, CART (Classification And 
Regression Tree) is decision tree learning. Trend analysis was performed by compar-
ing proportions of methods before 2008 and after 2008. Results: 5021 articles were 
found with the key word of comparativeness effectiveness. 227 articles had the key 
word of propensity. 56 articles had the key word of instrumental. 29 articles had the 
key word of inverse probability. 20 articles had key words of both propensity and 
instrumental. 12 articles had key words of both propensity and inverse probability. 6 
articles had key word of machine learning. 6 articles had key word of CART. No article 
was found to have the key word of support vector machine. Overall 6.2% of articles 
had one of the key words, indicating usage of confounder adjustment methods in 
comparative effectiveness research. Two articles had three key words of propensity, 
Inverse probability, and instrumental. Based on Chi-square test, significant increase 
of usage with P-value < .05 in trend has been observed. cOnclusiOns: Based on 
search result, significant increase in usage of confounder adjustment methods was 
observed since 2008. In a few articles, results from a few instrumental variable analy-
ses were conflicting with propensity score method warranting sensitivity analyses 
by employing various methods for adjustment of confounders. Also application 
of machine learning methods is recommended to find stable estimates of models 
used, especially to adjust for time dependent confounders.
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Objectives: Performance Outcomes (PerfOs) measure tasks performed by a 
patient under the instruction of a health-care professional. PerfOs used to sup-
port FDA label claims now require content validity evidence. This study explored 
patient experience and relevance of three elective total hip replacement (eTHR) 
PerfOs: the timed up and go (TUG), four step stair climb (4SC) and long stair climb 
(LSC). MethOds: Eight recent eTHR patients in the US were interviewed by tel-
ephone within 7 days of completing three PerfOs. Participants discussed their 
experience of completing the PerfOs; and how the movements, speed and level 
of difficulty corresponded to activities in their everyday lives. Interviews were 
audio-recorded, transcribed and systematically coded. Saturation was assessed by 
tabulated patient summaries from which new elements reported in each interview 
were identified. Results: The sample comprised six females and two males, with 
mean age 67 years. All participants related TUG movements to activities in their 
daily life (e.g. getting up to turn on the television) and most regularly climbed a 
few steps at home and in a similar way to the 4SC (e.g. use of handrail). Climbing 
12 or more steps (LSC) was less common. However, the majority recalled examples 
of this and felt the LSC accurately reflected movement and ability in their replaced 
hip. Two participants reported LSC completion increased their confidence and 
staircase use. Small differences between PerfOs and everyday activities/function 
were reported (e.g. TUG: the type of chair and turning towards rather than away 
from the replaced hip). Assessment of saturation suggested additional interviews 
might yield further varieties in patient experience but that sufficient consensus 
and depth was achieved to understand the relevance of the PerfOs to everyday 
function. cOnclusiOns: New methodological approaches developed to explore 
content validity of PerfOs demonstrate the connection between three PerfOs and 
daily function of eTHR patients.
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Objectives: When conducting a systematic review it is common practice to search 
for peer-reviewed publications and conference proceedings to identify studies rel-
evant to a research question. However, information about studies is increasingly 
available through other sources and can be of importance in systematic reviews. 
Clinical trials registries (CTRs) are increasingly providing unpublished results of 
studies that can be used in systematic reviews. Clinicaltrials.gov is one of the most 
commonly used CTRs and provides search facilities that enable the identification of 
trials through common search terms. In addition, there is the potential to request 
information from study sponsors through clinicalstudydatarequest.com. This 
website is supported by several prominent study sponsors and allows reviewers to 
request access to unpublished data which may be of importance in a systematic 
review. MethOds: We searched two disease areas (melanoma and juvenile idi-
opathic arthritis (JIA)) for instances where there were discrepancies in reporting 
of endpoints between peer-reviewed publications and the clinicaltrials.gov web-
page for corresponding trials. We submitted requests to clinicalstudyrequest.com 
for additional information on trials in both disease areas. Results: We identified 
additional reporting of subgroups as well as efficacy endpoints in clinicaltrials.gov 
that were not available in peer-reviewed publications. Results included one trial in 
melanoma (METRIC) which reported on only mixed line patients in a peer-reviewed 
publication; results stratified by previous therapy were available from the CTR. In 
addition, results from our search in JIA included additional reporting of efficacy out-
comes such as change in component scores from baseline. We detail length of time 
for response and issues with submission of data requests to clinicalstudyrequests.
com. cOnclusiOns: We conclude that sources other than peer-reviewed articles 
and conference abstracts should be considered when identifying study information 
that may be relevant to a particular review. Unpublished data may be available that 
can impact a systematic review and evidence synthesis.
